Krystal Biotech Inc (KRYS) Receives a Buy from William Blair

By Austin Angelo

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech Inc (KRYSResearch Report). The company’s shares closed last Monday at $42.20.

According to, Prasad is a 4-star analyst with an average return of 11.9% and a 49.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.

Krystal Biotech Inc has an analyst consensus of Strong Buy, with a price target consensus of $68.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $51.67 and a one-year low of $14.30. Currently, Krystal Biotech Inc has an average volume of 226.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.